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To prevail, the field may require a more rigorous understanding of HFpEF pathophysiology. This knowledge would serve interlocking objectives, from refining disease nosology to guiding discovery efforts. Knowledge of the cause(s) of symptoms and outcomes, coupled with the ability to measure them at scale, would enable the subtyping of patients by matching pathophysiology. Knowledge of these causal mechanisms would also enable rational therapy design, and, in a well selected population, improve the odds of a successful clinical trial.
A chief complaint among patients with HFpEF is exercise intolerance, a phenotype whose pathophysiology has been the subject of intense scrutiny. To this end, many investigators have applied a reductionist framework premised on defining exercise capacity as the rate of oxygen (O 2 ) consumption at peak exercise (Vo 2 Science author instructions page. Although it can be difficult to tease apart correlation from causation, the latter is made plausible by biological links between adiposity and anemia, muscle metabolism, and mitochondrial function. 
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